Sign up Australia
Proactive Investors - Run By Investors For Investors

Viralytics Ltd reveals positive cancer immunotherapy results

Viralytics Ltd (ASX:VLA) has received positive clinical results from the ongoing Phase 1b clinical trial of its cancer immunotherapy drug, CAVATAK, in combination checkpoint inhibitor KEYTRUDA.
Viralytics Ltd reveals positive cancer immunotherapy results
Viralytics Ltd reveals positive cancer immunotherapy results

CAVATAK is a novel cancer immunotherapy based on a proprietary cold virus that has been shown to preferentially infect and attack cancer cells.

The Phase 1b trial is designed to evaluate the safety and tolerability of CAVATAK in combination with KEYTRUDA, in 30 patients with advanced melanoma.

According to the preliminary data from the first 10 patients evaluable for best overall tumour response assessment, a disease control rate of 100% was demonstrated.

The response rates and side event profile of this immunotherapy combination compare favourably with other combination clinical trials in melanoma.

The increased activity of the drug in difficult-to treat, late-stage patients with a low rate of adverse events signals the potential to improve the treatment of melanoma and other cancer types.

Viralytics is well funded with $42 million in cash as at 30 September 2016.

The company’s share price has doubled since the beginning of 2016, last trading at $1.32.

View full VLA profile View Profile

Viralytics Timeline

Newswire
December 10 2015

Related Articles

test tubes
January 23 2018
Under former chief executive Peter George and his successor Shaun Chilton, it has been transformed via a series of well-judged, quickly integrated and, crucially, cash generative acquisitions
1513583223_shutterstock_86097949.jpg
December 18 2017
VAL201 is a treatment for metastatic prostate cancer and other solid tumours
couple in bed
March 14 2018
MED2002 is a rapid onset gel designed for those men where the current pill-based treatments aren’t appropriate, or carry significant side-effects

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use